First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

Clicks: 225
ID: 112245
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #20 of 32 articles by views in International journal of cancer

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Temsirolimus has long been the only approved first-line standard of care (SOC) with overall survival (OS) benefit in poor-risk patients with advanced or metastatic renal cell cancer (mRCC). However, tyrosine kinase inhibitors are also commonly used in clinical practice. Pazopanib is an SOC for first …
Reference Key
m2020internationalfirst-line Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Staehler M;Panic A;Goebell PJ;Merling M;Potthoff K;Herrmann E;de Geeter P;Vannier C;Hogrefe C;Marschner N;Grünwald V;;
Journal International journal of cancer
Year 2020
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/32738823
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:32738823 doi:10.1002/ijc.33238 michael staehler andrej panic viktor grünwald

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.